Inhibikase Therapeutics Inc Asset Resilience Ratio
Inhibikase Therapeutics Inc asset resilience ratio. Inhibikase Therapeutics Inc (IKT) has an Asset Resilience Ratio of 49.06% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IKT defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Inhibikase Therapeutics Inc (2021–2024)
Asset resilience ratio of Inhibikase Therapeutics Inc from 2021 to 2024. This chart shows how Inhibikase Therapeutics Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Inhibikase Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Inhibikase Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Inhibikase Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $39.05 Million | 49.06% |
| Total Liquid Assets | $39.05 Million | 49.06% |
Asset Resilience Insights
- Very High Liquidity: Inhibikase Therapeutics Inc maintains exceptional liquid asset reserves at 49.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Inhibikase Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Inhibikase Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Inhibikase Therapeutics Inc Asset Resilience Ratio by Year (2021–2024)
Inhibikase Therapeutics Inc asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Inhibikase Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 41.64% | $41.05 Million | $98.60 Million | +13.46pp |
| 2023-12-31 | 28.17% | $4.09 Million | $14.51 Million | -35.44pp |
| 2022-12-31 | 63.61% | $15.86 Million | $24.94 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $42.47 Million | -- |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more